BR0207302A - Trifluorometilpurinas como inibidores da fosfodiesterase 4 - Google Patents

Trifluorometilpurinas como inibidores da fosfodiesterase 4

Info

Publication number
BR0207302A
BR0207302A BR0207302-1A BR0207302A BR0207302A BR 0207302 A BR0207302 A BR 0207302A BR 0207302 A BR0207302 A BR 0207302A BR 0207302 A BR0207302 A BR 0207302A
Authority
BR
Brazil
Prior art keywords
phosphodiesterase
inhibitors
trifluoromethylpurines
trifluorometilpurins
formula
Prior art date
Application number
BR0207302-1A
Other languages
English (en)
Inventor
Ruiping Liu
Hans-J Rgen Ernst Hess
Allen Hopper
Yajing Rong
Ashok Tehim
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of BR0207302A publication Critical patent/BR0207302A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"TRIFLUOROMETILPURINAS COMO INIBIDORES DA FOSFODIESTERASE 4. A inibição da PDE4 é obtida por novos compostos da fórmula (I), na qual:
BR0207302-1A 2001-02-08 2002-02-08 Trifluorometilpurinas como inibidores da fosfodiesterase 4 BR0207302A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26719501P 2001-02-08 2001-02-08
US34482402P 2002-01-07 2002-01-07
PCT/US2002/022509 WO2002098878A1 (en) 2001-02-08 2002-02-08 Trifluoromethylpurines as phosphodiesterase 4 inhibitors

Publications (1)

Publication Number Publication Date
BR0207302A true BR0207302A (pt) 2004-02-10

Family

ID=26952286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207302-1A BR0207302A (pt) 2001-02-08 2002-02-08 Trifluorometilpurinas como inibidores da fosfodiesterase 4

Country Status (10)

Country Link
US (4) US7342021B2 (pt)
EP (1) EP1383767A1 (pt)
JP (1) JP4443215B2 (pt)
KR (1) KR100863622B1 (pt)
CN (1) CN100439370C (pt)
AU (1) AU2002313673B2 (pt)
BR (1) BR0207302A (pt)
CA (1) CA2438099A1 (pt)
MX (1) MXPA03007134A (pt)
WO (1) WO2002098878A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824632T2 (de) * 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
BR0207302A (pt) * 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CN100415747C (zh) * 2002-08-08 2008-09-03 记忆药物公司 磷酸二酯酶4抑制剂
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
FR2851247B1 (fr) * 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
KR20060056944A (ko) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
CN100447143C (zh) * 2003-08-15 2008-12-31 Irm责任有限公司 作为rtk抑制剂的6-取代的苯胺基嘌呤
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｒｔｋ阻害剤としての６−置換アニリノプリン類
JP2007517052A (ja) * 2003-12-23 2007-06-28 ノバルティス アクチエンゲゼルシャフト 二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
WO2005090354A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
GB0416699D0 (en) 2004-07-27 2004-09-01 Prometic Biosciences Ltd Prion protein ligands and methods of use
WO2006131768A2 (en) 2005-06-10 2006-12-14 Prometic Biosciences Limited Triazines as protein binding ligands
US7998981B2 (en) 2005-08-12 2011-08-16 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
CN101553467B (zh) 2007-01-08 2011-12-07 苏文生命科学有限公司 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008131501A2 (en) * 2007-04-27 2008-11-06 Katholieke Universiteit Leuven New anti-viral nucleoside analogs
AU2008246947B2 (en) 2007-05-03 2011-03-31 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands
CA2703157C (en) 2007-10-26 2013-02-05 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-ht6 ligands
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
MX2011002884A (es) 2008-09-17 2011-04-21 Suven Life Sciences Ltd Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
CN102227427B (zh) * 2008-11-27 2014-04-02 国立大学法人香川大学 环丁基嘌呤衍生物、血管新生促进剂、管腔形成促进剂、神经细胞生长促进剂及药品
MX2012007783A (es) 2010-01-05 2012-10-03 Suven Life Sciences Ltd Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
CN107260736A (zh) 2010-02-12 2017-10-20 株式会社ＡｓｋＡｔ 用于治疗痴呆的5‑ht4受体激动剂
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CN108395432A (zh) * 2018-01-15 2018-08-14 吴江信凯医药科技有限公司 一种2-三氟甲基-6-氨基嘌呤的制备方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
US12202815B2 (en) * 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
RU2746012C2 (ru) * 2019-05-13 2021-04-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917563A (en) 1970-02-17 1975-11-04 Japan Atomic Energy Res Inst Process for the production of high molecular weight polyoxymethylene by the polymerization of tetraoxane
US3919192A (en) 1972-05-22 1975-11-11 Icn Pharmaceuticals 5-Amino-4-substituted imidazole nucleotides
US3917583A (en) * 1972-08-04 1975-11-04 Icn Pharmaceuticals 2-Substituted cyclic AMP derivatives
AR205247A1 (es) 1973-02-07 1976-04-21 Icn Pharmaceuticals Procedimiento para preparar derivados de amp 2-substituidos
JPS6210085A (ja) 1985-07-05 1987-01-19 Yoshitomi Pharmaceut Ind Ltd トリフルオロメチルプリン誘導体
JPS62240622A (ja) 1986-04-11 1987-10-21 Asahi Glass Co Ltd 抗腫瘍剤
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5013829A (en) 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
JP3086912B2 (ja) 1991-06-20 2000-09-11 工業技術院長 フルオロアルキル基含有プリン誘導体及びその製造方法
CA2114114C (en) 1992-06-15 2005-05-03 Nigel Robert Arnold Beeley Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
DE4230755A1 (de) 1992-09-14 1994-03-17 Schering Ag Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (pt) 1992-12-23 1995-11-21 Celltech Ltd
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
US5744473A (en) 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
DE19702785A1 (de) 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
US6235736B1 (en) 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
DE19882893T1 (de) 1997-12-12 2001-02-22 Euro Celtique Sa Herstellung von 3-substituierten Adeninen
JP4160645B2 (ja) 1997-12-24 2008-10-01 大日本住友製薬株式会社 新規アデニン誘導体及びその医薬用途
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
JPH11264847A (ja) 1998-03-18 1999-09-28 Advantest Corp スペクトラム・アナライザ
JP2000072773A (ja) 1998-08-28 2000-03-07 Zeria Pharmaceut Co Ltd プリン誘導体
US6319928B1 (en) * 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DE19935209A1 (de) 1999-07-27 2001-02-08 Truss Michael C Verwendung von Substanzen, die den intrazellulären Gehalt von zyklischem Adenosinmonophosphat (cAMP) erhöhen oder die Aktivität cAMP-bindender Proteine stimulieren, zur Behandlung von Erkrankungen der Harnblase
GB0011802D0 (en) 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
BR0207302A (pt) 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CN100415747C (zh) 2002-08-08 2008-09-03 记忆药物公司 磷酸二酯酶4抑制剂
US7371737B2 (en) * 2004-09-09 2008-05-13 Solvay Pharmaceuticals, B.V. 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity

Also Published As

Publication number Publication date
KR20040008127A (ko) 2004-01-28
US20030045533A1 (en) 2003-03-06
CA2438099A1 (en) 2002-12-12
JP2004528391A (ja) 2004-09-16
KR100863622B1 (ko) 2008-10-15
US7342021B2 (en) 2008-03-11
EP1383767A1 (en) 2004-01-28
CN1501927A (zh) 2004-06-02
CN100439370C (zh) 2008-12-03
MXPA03007134A (es) 2004-10-15
JP4443215B2 (ja) 2010-03-31
US20080119495A1 (en) 2008-05-22
US20100010020A1 (en) 2010-01-14
US20040242598A1 (en) 2004-12-02
AU2002313673B2 (en) 2006-09-07
WO2002098878A1 (en) 2002-12-12
HK1066546A1 (zh) 2005-03-24

Similar Documents

Publication Publication Date Title
BRPI0416869A (pt) 5,7-diaminopirazolo '4,3-dipirimidinas com atividade de inibição de pde-5
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
BR0208062A (pt) Inibidores de metaloproteinase
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CY1113362T1 (el) Διαρυλ-αιθερες, ως ανταγωνιστης οπιοειδους υποδοχεως
SE0000540D0 (sv) New compounds
BR0214268A (pt) Aperfeiçoamentos em relação a abrilhantadores ópticos
HK1053831A1 (zh) 作为治疗药物的激酶抑制剂
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
SI1392642T1 (sl) Nove spojine kot protivnetna, imunomodulacijska in antiproliferativna sredstva
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
BR0313969A (pt) Inibidores de oxitocina
EP1314712A4 (en) NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT
ATE411287T1 (de) Neue metallproteinaseinhibitoren
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
NO20040388L (no) Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
SE0101082D0 (sv) Novel use
BR0108501A (pt) Compostos de n-hidróxiformamidas substituìdos por piperidina e piperazina como agentes inibidores de metaloproteinase
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 10A. ANUIDADE(S),

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.